Economy News Ozempic Maker Novo Nordisk Isn T Just Europe S Second Most Valuable Company It Is Also Singlehandedly Boosting Denmark S Economy

Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from U.S. pharma giant Pfizer. On Monday, Pfizer said it had filed a second ... Read More

Novo Nordisk to offer select doses of Ozempic, Wegovy at a steep discount

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month. Then the monthly cost will rise to $349. Read More

Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharma

On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to $199 when patients pay cash through Novo’s ... Read More

Ozempic Maker Novo Nordisk Lowers Growth Outlook

Novo Nordisk NOVO.B1.57%increase; green up pointing triangle lowered its sales and profit guidance as the pharmaceutical company contends with intensifying competition, pricing pressure and copycat ... Read More

Ozempic Maker Novo Nordisk Lowers Growth Outlook for Blockbuster Drugs — 2nd Update

Novo Nordisk narrowed its earnings guidance as intensifying competition, pricing pressure and copycat versions of its blockbuster Ozempic and Wegovy drugs hold back sales. Compounding pharmacies in ... Read More

Ozempic Maker Novo Nordisk Lowers 2025 Outlook After Tepid Results

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results. The ... Read More

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion. Sales increased by 5 ... Read More

Ozempic Maker Novo Nordisk Faces Board Shakeup

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market. Read More

Ozempic Maker Novo Nordisk Lowers 2025 Outlook After Tepid Results

Danish pharmaceutical giant Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, lowered its 2025 outlook for the fourth time this year on Wednesday after posting tepid third-quarter results. Read More

Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma giant. Read More